相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1919
已完成
5
83.3%
招募中
1
16.7%
暂无批准数据
- Upsher-Smith Laboratories launched a generic version of Restasis (cyclosporine ophthalmic emulsion 0.05%) in May 2026, entering a market worth approximately $1.9 billion in annual U.S. sales. - The FDA approved Bora Pharmaceuticals' abbreviated new drug application for the therapeutically equivalent product in January 2026, with the generic available in 30-count and 60-count single-use vial packages. - This launch represents Upsher-Smith's continued portfolio diversification strategy, strengthening their ophthalmic offerings as a subsidiary of Bora Pharmaceuticals. - The company also recently launched a generic version of Ciprodex ear drops, marking their first prescription ear drop suspension and targeting a $118 million market segment.
- Bora Pharmaceuticals has acquired Pyros Pharmaceuticals, a U.S.-based company focused on developing treatments for rare diseases, including infantile spasms. - Pyros recently launched Vigafyde (vigabatrin) oral solution, the first premixed, ready-to-use vigabatrin formulation approved by the FDA for infantile spasms. - The acquisition strengthens Bora's portfolio in the central nervous system (CNS) space, particularly in pediatric treatments, following previous acquisitions of Upsher-Smith and TWi Pharmaceuticals. - Bora aims to leverage Pyros' R&D capabilities and Upsher-Smith's market presence to enhance treatment satisfaction and patient outcomes with Vigafyde.
